New clues reveal how cells respond to stress
Inflammasome protein complexes form in response to signals associated with danger, such as an infection or environmental stress, and trigger the innate immune response. The serine protease dipeptidyl peptidase 9, or DPP9, forms a dimer in its active conformation and interacts with components of inflammasomes to prevent unnecessary activation. Scientists know that synthetic inhibitors of DPP9 activate certain inflammasomes. However, whether a cell-intrinsic molecule can inhibit this enzyme remains an open question. Therefore, Lydia Tsamouri, Jeffrey Hsiao and colleagues from the Weill Cornell Graduate School of Medical Sciences and Memorial Sloan Kettering Cancer Center investigated DPP9 interaction partners. They examined a connection between DPP9 and redox sensor KEAP1 in their recent Journal of Biological Chemistry article.
Using a fluorogenic probe that functions as a DPP9 substrate, the authors established that KEAP1 inhibits DPP9 activity in cells. They also found that KEAP1 can only inhibit DPP9 when both are introduced into cells at the same time via transfection with complementary DNA, or cDNA, that encodes each protein, before DPP9 dimerizes; newly introduced KEAP1 could not inhibit DPP9 already present in cells. The researchers hypothesized that KEAP1 interacts with DPP9 in a state different from its folded dimeric structure and that a cellular event or biomolecule could force DPP9 to adopt this alternative conformation. They tested multiple compounds, including electron transport chain inhibitors and oxidants like hydrogen peroxide, but they have not yet found a condition that leads to KEAP1–DPP9 complex formation and DPP9 inactivation.
Future experiments will focus on identifying a signal or molecules that could change DPP9’s conformation and whether the DPP9–KEAP1 interaction directly initiates inflammasome activation. Outlining the full DPP9 pathway involving inflammasomes will help scientists understand how cells convert danger signals into immune action and restrain unnecessary activation.
Enjoy reading ASBMB Today?
Become a member to receive the print edition four times a year and the digital edition monthly.
Learn moreGet the latest from ASBMB Today
Enter your email address, and we’ll send you a weekly email with recent articles, interviews and more.
Latest in Science
Science highlights or most popular articles

Cholesterol regulatory genes predict liver transplant outcomes
Researchers identify a link between cholesterol-regulating genes and liver transplant success, which could improve donor screening and patient outcomes.

Lipid signatures for a rare neurological disorder
Researchers find distinct lipid patterns linked to a rare autoimmune neurological disorder, offering hope for effective targeted therapies for patients.

Disease-linked mutations disrupt protein phase behavior
Researchers find that pathogenic missense mutations are enriched threefold in phrase-separating intrinsically disordered regions of proteins.

The dual role of asprosin in chronic fatty liver disease
Researchers uncover a hormone called asprosin that may serve as a potential biomarker for the diagnosis of chronic fatty liver disease and monitoring disease progression.

Novel inhibitor targets RAS-driven cancers
Researchers in Louisville identify a small-molecule drug that blocks RALGEF signaling downstream of mutant RAS. The compound suppresses tumor growth with low toxicity, revealing a new therapeutic strategy for RAS-driven malignancies.

Catching tau in the act
Using a new proximity-labeling approach, researchers reveal how tangles of the brain-associated protein tau may disrupt RNA biology long before neurons die.